Unilever (UL)
(Delayed Data from NYSE)
$65.35 USD
-0.24 (-0.37%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $65.49 +0.14 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.35 USD
-0.24 (-0.37%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $65.49 +0.14 (0.21%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights Prosus, Intuitive Surgical and Unilever
by Zacks Equity Research
Prosus, Intuitive Surgical and Unilever are included in this Analyst Blog.
August U.S. CPI Data: Global Week Ahead
by John Blank
Investors are on edge -- ahead of more key macro events -- that could shape the tone for trading in the weeks ahead.
Accenture and Unilever Collaborate on Generative AI Platform
by Zacks Equity Research
ACN's collaboration with UL marks a strategic move toward strengthening its position as a leader in digital transformation.
Best Growth Stocks to Buy for September 6th
by Zacks Equity Research
CARG, AEYE and UL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 6, 2024.
The Zacks Analyst Blog Highlights American Water Works, NiSource, Evergy, Unilever and Flowers Foods
by Zacks Equity Research
American Water Works, NiSource, Evergy, Unilever and Flowers Foods are part of the Zacks top Analyst Blog.
Zacks.com featured highlights include Erie Indemnity, Sprouts Farmers Market, Newmont and Unilever
by Zacks Equity Research
Erie Indemnity, Sprouts Farmers Market, Newmont and Unilever are part of the Zacks Screen of the Week article.
5 Defensive Stocks With the Most Upside as Market Volatility Returns
by Ritujay Ghosh
Defensive stocks like AWK, NI, EVRG, UL and FLO are a safe bet during times of market volatility.
Volatility Concerns? Bet on 4 Low-Beta Stocks: ERIE, SFM, NEM, UL
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. ERIE, SFM, NEM and UL are well-poised to gain.
Unilever PLC (UL) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Unilever PLC (UL) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for September 4th
by Zacks Equity Research
FLIC, MHO, SMFG, PED and UL have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2024.
Best Growth Stocks to Buy for September 4th
by Zacks Equity Research
CSGS, IBKR and UL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 4, 2024.
Unilever (UL) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Unilever (UL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Procter & Gamble (PG) Trades Near 52-Week High: Should You Buy?
by Rajani Lohia
Procter & Gamble (PG) witnesses consistent growth, with the stock creating new 52-week highs in less than two months.
Procter & Gamble (PG) Hits 52-Week High: Buy, Hold or Sell?
by Rajani Lohia
After Procter & Gamble (PG) hits a 52-week high, we assess whether the current level warrants an opportunity to accumulate shares, hold positions or book profits.
A. O. Smith (AOS) to Buy Pureit & Expand Presence in India
by Zacks Equity Research
A. O. Smith's (AOS) acquisition of Pureit is set to strengthen its product offerings and boost its position in the water treatment industry.
Best Income Stocks to Buy for December 5th
by Zacks Equity Research
UL, SMMF and TM made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 5, 2023.
Down -5.3% in 4 Weeks, Here's Why Unilever PLC (UL) Looks Ripe for a Turnaround
by Zacks Equity Research
Unilever PLC (UL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
6 ETF Areas & Stocks to Win on Upbeat August Retail Sales
by Sanghamitra Saha
Retail sales in the United States grew 0.6% sequentially in August 2023, beating forecasts of a 0.2% advance.
ETF Areas & Stocks to Win on Upbeat July Retail Sales
by Sanghamitra Saha
Retail sales in the United States gained 0.7% sequentially in July of 2023, marking a fourth successive rise.
Zacks Industry Outlook Highlights Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive
by Zacks Equity Research
Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive have been highlighted in this Industry Outlook article.
4 Soaps & Cleaning Materials Stocks to Gain as Industry Catches On
by Avisekh Bhattacharjee
The soap and cleaning materials industry benefits from revived demand trends, pricing actions, innovation, digital transformation and brand building. Players like UL, CHD, PG and CL look well-poised.
Are Consumer Staples Stocks Lagging McCormick & Company (MKC) This Year?
by Zacks Equity Research
Here is how McCormick (MKC) and Unilever PLC (UL) have performed compared to their sector so far this year.
4 Sector ETFs & Stocks to Win on March Retail Sales
by Sanghamitra Saha
In March 2023, U.S. retail sales experienced a 1% sequential decline, better than market expectations of a 0.4% decrease.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
by Zacks Equity Research
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug
by Zacks Equity Research
The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.